FGF21 and metabolic dysfunction-associated steatotic liver disease: Given that FGF21 is recognized as a promising biomarker for the diagnosis and staging of NAFLD and that its elevated levels in patients with hepatic steatosis may indicate a protective response to lipotoxicity, research suggests that exogenous FGF21 could potentially slow the progression of these diseases.